.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD51_CefotaximeAndBetaLactama.CefotaximeAndBetaLactama

Information

Combination of cefotaxime, a third-generation cephalosporin antibiotic, with a beta-lactamase inhibitor used to treat a broad spectrum of bacterial infections, particularly those caused by beta-lactamase producing organisms. Cefotaxime is approved for clinical use, but this fixed ATC code refers to the combination with any beta-lactamase inhibitor, which may not be widely approved or formulated commercially.

Pharmacokinetics

Pharmacokinetic parameters estimated from published data about cefotaxime given intravenously in healthy adults, as no published PK data available for fixed combination with beta-lactamase inhibitor. Parameters are estimations extrapolated from cefotaxime studies only.

References

1. Smekal, AK, et al., & Nielsen, EI (2025). Short, extended and continuous infusion of β-lactams: predicted impact on target attainment and risk for toxicity in an ICU patient cohort. The Journal of antimicrobial chemotherapy 80(3) 876–884. DOI:10.1093/jac/dkaf013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39847494

Revisions

• 06/2025 initial generated model